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A B S T R A C T
The concentration levels of salivary calcium, magnesium and zinc can vary in different localized oral, as well as sys-
temic diseases and conditions. So far changes in the concentration levels of specific electrolytes in stimulated parotid sa-
liva in HIV-positive/AIDS patients have been proven. The objective of this research was not only to study the concentra-
tion levels of calcium in non-stimulated total saliva, but also the concentration levels of magnesium and zinc, which have
not been studied so far, and the influence of antiretroviral therapy (HAART). This research was conducted on 60 healthy
subjects with an average age of 40.4 years, and 60 HIV-positive patients with an average age of 43.7 years, 45 of whom
took HAART therapy. The concentration levels of calcium, magnesium and zinc in saliva were determined by means of
an atomic absorption spectrophotometry. No significant differences in the levels of excreted saliva/5 minutes (p=0.116),
the concentration levels of salivary calcium (p=0.713), magnesium (p=0.600), nor zinc (p=0.162) were found between
HIV-positive patients and the control group. No any correlation was determined between all three types of electrolytes and
the number of CD4+ cells, nor the number of HIV-virus copies in peripheral blood of patients. Within the HIV-positive
group, with respect to HAART therapy, no differences were found in the concentration levels of salivary magnesium
(p=0.588), nor zinc (p=0.096). However, the concentration levels of salivary calcium were significantly higher in HIV-po-
sitive patients who underwent HAART treatment (p=0.004). The results of this research show that HIV, as a systematic
infection, does not cause changes in the excretion of magnesium, zinc nor calcium in non-stimulated total saliva. Fur-
thermore, it has been proven that HAART treatment does not cause changes in the concentration levels of magnesium or
zinc, but can cause an elevation in the concentration level of saliva, which could be related to the calcium mobilization in
blood.
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Introduction
Saliva, as a product of salivary glands, not only has a
specific physiological function, but is also an accessible
medium for diagnosing of different pathological condi-
tions. Alongside water and organic matter, important ele-
ments of saliva are inorganic components whose concen-
tration levels are in correlation with many pathological
conditions in human body1–7. The concentration levels of
salivary calcium can vary in systemic diseases and condi-
tions. However, with certain conditions like asthma,
Sjögren’s syndrome and familial disautonomy no dis-
crepancy was determined8,10. On the other hand, the con-
centration levels of salivary calcium in patients suffering
from diabetes mellitus can be both elevated and dec-
reased5,11. The decreased concentration levels of salivary
calcium are found in menopausal women12. The concen-
tration levels of salivary magnesium can also be related
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to many diseases. In patients suffering from diabetes
mellitus5, GVHD (Graft-versus-host disease; GVHD)13, and
those who have been receiving nourishment via naso-
gastric probe over a longer period of time14, the concen-
tration levels of salivary magnesium are elevated. In pa-
tients suffering from migraine15, and those prone to the
development of sialoliths4, the concentration levels of
salivary magnesium exhibit a decrease, while with the
patients suffering from Sjögren’s syndrome no discrep-
ancy in the levels of electrolytes in saliva was found15.
Certain diseases and conditions exhibit discrepancy in
the concentration levels of several electrolytes simulta-
neously. Accordingly, the concentration levels of salivary
calcium and magnesium are elevated in patients suffer-
ing from systematic lupus erythematosus16, and perio-
dontal disease17, while decreased in patients with hyper-
tesion18. Discrepancy in the concentration levels of sali-
vary calcium, magnesium and zinc were not found in pa-
tients with juvenile recurrent parotitis,19 but in patients
with periodontitis lower concentration levels of calcium
in parotid saliva were found20. Zinc is another type of
electrolytes in saliva which plays an important role in the
prevention of tartar development. Decreased concentra-
tion levels of zinc are found in patients suffering from di-
abetes and taste disorder5,21.
The concentration levels of salivary electrolytes in
HIV-positive/AIDS patients have not been completely
recognized. Total saliva contains elevated concentration
levels of sodium, with unchanged concentration levels of
potassium and phosphate22. Stimulated parotid saliva ex-
hibits elevated concentration levels of sodium and chlo-
ride, with unvarying concentration levels of potassium,
phosphate and calcium23,24. On the other hand, some re-
searches have discovered unchanged concentration lev-
els of chloride25. So far, there have been no documented
data regarding the concentration levels of salivary zinc
and magnesium in HIV-positive patients. The objective
of this research was to determine the concentration lev-
els of salivary calcium, magnesium and zinc in HIV-posi-
tive subjects, as well as the influences of antiretroviral
therapy.
Subjects and Methods
This research was conducted on 60 voluntary HIV-
positive subjects, 47 male and 13 female, with an average
age of 44.7 years (ranging from 26 to 71 years of age).
The number of CD4+ lymphocytes varied from 25–744/mL,
with the number of HIV virus copies in blood ranging
from 0–468,000/mL. Out of 60 HIV-positive subjects, 45
took antiretroviral therapy, according to current treat-
ment guidelines, HAART (Highly Active Antiretroviral
Therapy; HAART).
The control group consisted of 60 healthy subjects, 37
male and 23 female, with an average age of 40.4 years
(ranging from 21 to 79 years of age). None of them had
any clinically visible pathological changes in the mucous
membrane of the oral cavity.
Non-stimulated total saliva was collected according to
Wu-Wang et al.26, i.e. in calibrated test tubes during a pe-
riod of 5 minutes, between 8 am and 11 am, was being ex-
amined. After the syalometric assessment of amount, the
samples were frozen at –70 °C until the start of the analy-
sis. The concentration levels of calcium, magnesium and
zinc were determined by atomic absorption spectropho-
tometry according to aforementioned methods27–30.
The results were presented descriptively, as the mean
value ± standard deviation. Due to the exponential in-
crease in the number of HIV virus copies in peripheral
blood it was presented as a decimal logarithm. Depen-
ding on the type of variables and the principal of data dis-
tribution, the differences between the two groups were
examined using c2 test, t-test and Pearson’s exact corre-
lation test.
Results
There was no significant difference between the HIV-
-positive group and the control group according to age
(t=1.486; p=0.140), nor sex (c2=3.214; p=0.072). By
means of syalometric assessment, the average amount of
1.14 ± 0.31 ml saliva/5 minutes was collected in HIV-posi-
tive subjects, and 1.26 ± 0.49 ml saliva/5 minutes in the
control group, with no significant difference between the
two groups (t=–1.585; p=0.116) (Table 1).
Average concentration levels of salivary magnesium
in HIV-positive subjects was 0.276 ± 0.149 mmol/L, and
0.262 ± 0.152 mmol/L in the control group, with no sig-
nificant difference between the two groups (t=0,526;
p=0.600). The concentration levels of salivary calcium in
HIV-positive subjects was 0.756 ± 0.442 mmol/L, and
0.787 ± 0.453 mmol/L in the control group, once again
with no significant difference between the two groups
(t=–0.369; p=0.713). The concentration levels of sali-
vary zinc in HIV-positive subjects averaged 1.831 ± 1.195
mmol/L, in addition to 1.566 ± 837 mmol/L in the control
group, with no significant difference between the two
groups (t=1.408; p=0.162) (Table 1).
The concentration levels of salivary electrolytes were
compared between the HIV-positive subjects, in refer-
ence to antiretroviral therapy (Table 2). The concentra-
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TABLE 1
THE AMOUNT OF COLLECTED SALIVA AND THE CONCENTRA-
TION LEVELS OF SPECIFIC SALIVARY ELECTROLYTES IN







(mL/5 minutes) 1.14 ± 0.31 1.26 ± 2.34
0.116
Magnesium (mmol/L) 0.276 ± 0.149 0.262 ± 0.153 0.600
Calcium (mmol/L) 0.756 ± 0.442 0.787 ± 0.453 0.713
Zinc (ìmol/L) 1.831 ± 1.195 1.566 ± 0.837 0.162
1 mean ± standard deviation
* t-test
tion levels of magnesium in saliva of those patients who
took antiretroviral therapy was 0.282 ± 0.151 mmol/L,
and in those who did not take the therapy 0.258 ± 0.149
mmol/L, with no significant difference between the two
groups (t=–0.545; p=0.588). The concentration levels of
calcium in saliva of patients who took antiretroviral ther-
apy ranged between 0.850 ± 0.464 mmol/L, as opposed to
those who did not take the therapy, 0.477 ± 0.190 mmol/L,
with a statistically significant difference (t=–3.019; p=
0.004). The concentration level of zinc in saliva of pa-
tients who took antiretroviral therapy, was 1.980 ± 1.209
mmol/L, i.e. 1.387 ± 1.067 mmol/L in those who did not,
once again with no significant difference between the
two groups (t=–1.691; p=0.096) (Table 2).
Pearson’s exact correlation test was use to examine
the concentration levels of salivary magnesium, calcium
and zinc in relation to the number of CD4+ lymphocytes
in peripheral blood of the HIV-positive subjects. No sig-
nificant correlation between the number of CD4+ of
lymphocytes in peripheral blood of HIV-positive patients
and the concentration levels of magnesium (r=–0.09;
p=0.495), calcium (r=–0.06; p=0.651) and zinc in saliva
(r=–0.18; p=0.889) was determined. In the end, Pear-
son’s exact correlation test was use to examine concen-
tration levels of magnesium, calcium and zinc in rela-
tions to the number of HIV virus copies in peripheral
blood in HIV-positive subjects. Similarly, no significant
correlation between the number of HIV virus copies and
the concen- tration levels of magnesium (r=–0.272; p=
0.188), calcium (r=0.101; p=0.631) nor zinc in saliva of
HIV-positive subjects (r=0.032; p=0.880) was determi-
ned (Table 3).
Discussion
No significant difference in the concentration levels of
magnesium, calcium nor zinc between HIV-positive pa-
tients and the healthy subjects were determined in this
research. Other researches so far have shown that the
concentration levels of specific electrolytes in saliva can
be a result of local, as well as systematic factors4,5,9,10,12,
15,17,18,20,21. Certain, mainly localized, diseases, like in
children suffering from juvenile recurrent parotitis19, do
not exhibit changes in concentration levels of salivary
calcium, magnesium nor zinc. On the other hand, Ben-
-Aryeh et al. believe that elevated concentration levels of
salivary calcium, magnesium and sodium in patients suf-
fering from systematic lupus erythematosus could be an
indicator of the development of subclinical disease of sali-
vary glands, within the original disease16. Nager et al.
have identified elevated concentration levels of salivary
potassium, calcium and phosphate in patients suffering
from GVHD13. After two weeks of pilocarpine treatment,
these values normalized, which made them reach a con-
clusion that changes in the concentration levels of sali-
vary electrolytes are an indicator of subclinical disease of
salivary glands, within the original disease, GVHD. HIV-
-disease/AIDS is a systematic infective disease which
causes changes in organic, but also inorganic composi-
tion of saliva. However, most researches so far have been
directed towards salivary immunoglobulin, while only a
few researches have studied salivary electrolytes in HIV-
-positive/AIDS patients31,32. Most researches have shown
elevated concentration levels of salivary chloride23,24.
Apart from that, elevated concentration levels of sodium,
with no simultaneous changes in the concentration levels
of potassium and phosphate have also been discovered in
the stimulated total saliva of HIV-positive subjects22. In
stimulated parotid saliva elevated concentration levels of
sodium, and, at the same time, decreased concentration
levels of potassium were found. In another research, Yeh
et al. discovered the elevated concentration levels of chlo-
ride in both non-stimulated and stimulated parotid, as
well as in submandibular saliva of HIV-positive pa-
tients24. Mandel et al. discovered elevated concentration
levels of sodium and chloride in stimulated parotid sa-
liva, while the concentration levels of potassium and
phosphate retained their values23. They also discovered
an unchanged concentration level of calcium in stimu-
lated parotid saliva, similar to our findings for non-stim-
ulated total saliva. Lin et al. showed neither changes in
the concentration levels of chloride and potassium in
stimulated parotid saliva of HIV-positive patients, nor
changes in the concentration level of calcium, similar to
our findings for non-stimulated total saliva25.
The concentration levels of salivary magnesium, which
have not been studied in HIV-positive patients so far, ex-
hibited no change regarding the illness, similar to certain
autoimmune diseases, such as Sjögren’s syndrome15, in
contrast to other autoimmune diseases, such as lupus
erythematosus, where concentration levels of salivary
magnesium were elevated16. Similarly, the concentration
levels of salivary zinc, which has neither been studied in
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TABLE 2
THE CONCENTRATION LEVEL OF SALIVARY ELECTROLYTES IN
HIV-POSITIVE PATIENTS WHO TOOK ANTIRETROVIAL
THERAPY (HIGHLY ACTIVE ANTIRETROVIRAL THERAPY;






Magnesium (mmol/L) 0.282 ± 0.151 0.258 ± 0.149 0.588
Calcium (mmol/L) 0.850 ± 0.464 0.477 ± 0.190 0.004
Zinc (ìmol/L) 1.980 ± 1.209 1.387 ± 1.067 0.096
1 mean ± standard deviation.
* t-test
TABLE 3
PEARSON’S CORRELATION OF THE NUMBER OF CD4+ LYM-
PHOCYTES AND THE NUMBER OF HIV VIRUS COPIES IN
HIV-POSITIVE SUBJECTS WITH THE CONCENTRATION LEVELS











* p value of Pearson’s correlation
HIV-positive patients so far, exhibited no changes in rela-
tions to the disease observed in this research, as well as
other, mostly localized, oral diseases, such as juvenile re-
current parotitis19, and as opposed to certain systemic
diseases like diabetes, which exhibit decreased concen-
tration levels of salivary zinc5.
Though patients were not classified according to the
extent of HIV infection, the progress of the disease was
evident from the concentration levels of CD4+ cells and
the number of HIV virus copies in peripheral blood33. Ac-
cording to the our research, these variables were in no
correlation with the concentration levels of either elec-
trolyte studied, so we believe that their concentration
level is not related to the progress of the disease as well.
The results of this research show a significant eleva-
tion in the concentration levels of salivary calcium in
HIV-positive patients who took antiretroviral therapy.
HIV-positive patients are known to be prone to osteo-
penia. Low Body Mass Index, weight loss, smoking, alco-
holism and drug abuse, as well as menstrual cycle disor-
der are listed as possible reasons. Apart from that, chronic
inflammations are known to be linked to progressive
bone resorption, malabsorption of calcium, lipodystro-
phia and lactic acidemia which additionally contribute to
osteopenia.34,35 Progressive osteopenia in HIV-positive
patients also can be caused by antiretroviral medica-
tions, which have a negative effect on bone metabolism
and can lead to osteoporosis, especially in patients who
take proteases inhibitors.36,37 The cause of antiretroviral
medications effect on bone structure is still unclear.
There is a possibility that it affects the remodeling of
bones directly, and/or the metabolism of vitamin D, indi-
rectly. Whether all these effects are related to the calcium
mobilization in blood, to the concentration levels of
bounded and ionized calcium in blood, and finally to the
elevation of concentration level of this electrolyte in sa-
liva remains to be seen.
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HIV INFEKCIJA, ZA RAZLIKU OD ANTIRETROVIRALNE TERAPIJE, NE UZROKUJE PROMJENE
KONCENTRACIJE NEKIH SALIVARNIH ELEKTROLITA
S A @ E T A K
Koncentracija salivarnog kalcija, magnezija i cinka mo`e biti promijenjena u raznim lokalnim oralnim kao i sus-
tavnim bolestima i stanjima. Poznato je da se u stimuliranoj parotidnoj slini kod HIV-oboljelih/AIDSA nalaze promjene
koncentracije nekih elektrolita. Svrha ovog istra`ivanja bila je istra`iti koncentracije kalcija u nestimuliranoj ukupnoj
slini kao i do sada neistra`ivanih koncentracija magnezija i cinka te utjecaj antiretroviralne terapije (HAART). U stu-
diju je uklju~eno 60 zdravih ispitanika prosje~ne dobi 40.4 godina i 60 HIV-pozitivnih bolesnika prosje~ne dobi 43,7
godina, od kojih su 45 primali HAART. Koncentracija kalcija, magnezija i cinka u slini odre|ena je atomskom apsorp-
cijskom spektrofotometrijom. Nije na|eno zna~ajnih razlika izme|u HIV-pozitivnih bolesnika i kontrolnih ispitanika u
u koli~ini izlu~ene sline/5 minuta (p=0,116), kao niti u koncentraciji salivarnog kalcija (p=0,713), magnezija (p=0,600)
i cinka (p=0,162). Unutar skupine HIV-pozitivnih s obzirom na terapiju s HAART nije bilo razlika u koncentraciji
salivarnog magnezija (p=0,588) i cinka (p=0,096), no koncentracija salivarnog kalcija bila je zna~ajno vi{a kod HIV-po-
zitivnih bolesnika koji su primali HAART (p=0,004). S druge strane, nije ustanovljena korelacija izme|u sva tri ispiti-
vana elektrolita i broja CD4+ stanica kao niti broja kopija virusa HIV-a u perifernoj krvi. Rezultati istra`ivanja pokazu-
ju da HIV kao sustavna infekcija ne izaziva promjene u lu~enju magnezija, cinka i kalcija u nestimuliranoj ukupnoj slini
kao. Tako|er, pokazano je da HAART ne izaziva promjene koncentrcije magnezija i cinka ali mo`e uzrokovati povi{enu
koncentraciju kalcija u slini, {to bi moglo biti povezano s osteopenijom i mobilizacijom kalcija u krvi osteopenijom.
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